Financhill
Sell
10

DARE Quote, Financials, Valuation and Earnings

Last price:
$2.37
Seasonality move :
-21.86%
Day range:
$2.35 - $2.62
52-week range:
$2.35 - $4.81
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
771.15x
P/B ratio:
11.45x
Volume:
101.7K
Avg. volume:
34.8K
1-year change:
-46.52%
Market cap:
$20.9M
Revenue:
$9.8K
EPS (TTM):
-$0.18

Earnings Data

Next earnings date for DARE
Aug 12
2025
Most recent earnings per share
-$0.50
Beat by $0.08
(May 13/2025)
Consensus Estimate
-$0.58
(May 13/2025)

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

DARE Quarterly Earnings History

Date Quarter Revenue Forecast Actual Revenue Reported EPS Consensus EPS Beat/Miss
08/12/2025 Q2 $141.5K -- -- -$0.52 --
05/13/2025 Q1 -- $25.4K -$0.50 -$0.58 $0.08
03/31/2025 Q4 $1M -$63.7K -$0.65 -$0.63 -$0.02
11/14/2024 Q3 $2M $41.7K -$0.55 -$0.71 $0.16
08/12/2024 Q2 $189.3K $22.4K $1.52 -$0.66 $2.18
05/14/2024 Q1 $260.5K $9.3K -$0.81 -$0.72 -$0.09
03/28/2024 Q4 $1.5M $1.8M -$0.70 -$0.96 $0.26
11/09/2023 Q3 $385.7K $1M -$1.09 -$1.20 $0.11
08/10/2023 Q2 $900K -- -$1.22 -$1.08 -$0.14
05/11/2023 Q1 -- -- -$1.08 -- --
03/30/2023 Q4 -- -- -$2.28 -- --
11/10/2022 Q3 -- -- -$0.96 -- --
08/09/2022 Q2 -- $10M $0.06 -- --
05/12/2022 Q1 -- -- -$1.20 -- --
03/31/2022 Q4 -- -- -$2.16 -- --
11/10/2021 Q3 -- -- -$2.16 -- --
08/12/2021 Q2 -- -- -$2.16 -- --
05/13/2021 Q1 -- -- -$1.92 -- --
03/30/2021 Q4 -- -- -$2.64 -- --
11/12/2020 Q3 -- -- -$2.88 -- --
08/12/2020 Q2 -- -- -$3.24 -- --
03/31/2020 Q1 -- -- -$2.16 -- --
12/31/2019 Q4 -- -- -$2.52 -- --
09/30/2019 Q3 -- -- -$2.40 -- --
06/30/2019 Q2 -- -- -$3.48 -- --
03/31/2019 Q1 -- -- -$3.24 -- --
12/31/2018 Q4 -- -- -$3.00 -- --
09/30/2018 Q3 -- -- -$2.76 -- --
06/30/2018 Q2 -- -- -$3.84 -- --
03/31/2018 Q1 -- -- -$10.56 -- --
12/31/2017 Q4 -- -- -$18.12 -- --
09/30/2017 Q3 -- -- -$3.96 -- --
06/30/2017 Q2 -- -- -$6.60 -- --
03/31/2017 Q1 -- -- -$3.24 -- --
12/31/2016 Q4 -- -- -$2.76 -- --
09/30/2016 Q3 -- -- -$0.24 -- --
06/30/2016 Q2 -- -- -$47.64 -- --
03/31/2016 Q1 -- -- -$58.80 -- --
12/31/2015 Q4 -- -- -$46.80 -- --
09/30/2015 Q3 -- -- -$46.80 -- --
06/30/2015 Q2 -- -- -$44.40 -- --

Dare Bioscience Earnings Questions

  • How Much did Dare Bioscience Generate in Revenue Last Quarter?

    Dare Bioscience reported $25.4K worth of top line sales in its most recent quarter.

  • Did Dare Bioscience Beat Earnings Last Quarter?

    Dare Bioscience announced earnings per share of -$0.50 which represents a beat of analyst forecast a -$0.58 per share.

  • Is Dare Bioscience Profitable?

    Dare Bioscience reported $25.4K that represents $0.00 per share over the last quarter.

  • What is the Analyst Consensus for Dare Bioscience EPS Next Year?

    Dare Bioscience's earnings are forecast to decrease from -$0.48 per share to -$0.46 per share next year representing a decrease of -295.83%.

  • When is Dare Bioscience's Earnings Date?

    Dare Bioscience's next earnings date is August 12, 2025.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Is Planet Labs Stock Up Today?
Why Is Planet Labs Stock Up Today?

Planet Labs (NYSE: PL) opened Friday trading with an unmistakable…

Is Coherent Stock Breaking Out?
Is Coherent Stock Breaking Out?

Coherent (NYSE: COHR) has spent the better part of two years…

What Is The Long-term Outlook for AMC Stock?
What Is The Long-term Outlook for AMC Stock?

Meme stock extraordinaire AMC Entertainment Holdings, Inc. (NYSE:AMC) has long…

Stock Ideas

Buy
65
Is NVDA Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 54x

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 42x

Sell
45
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Sell
49
NKE alert for Jun 28

Nike [NKE] is up 15.29% over the past day.

Buy
81
KTOS alert for Jun 28

Kratos Defense & Security Solutions [KTOS] is up 10.89% over the past day.

Sell
44
GDXU alert for Jun 28

MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 10.89% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock